Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Effects of CPG-oligodeoxynucleotides in Chronic Inflammation and Remodeling of Airway in a Murine Model of Bronchial Asthma

기관지천식의 마우스모델에서 CPG-oligodeoxynucleotides의 기도의 만성염증 및 기도재구성에 대한 영향

  • Song, So Hyang (Department of Internal Medicine, The Catholic University of Korea) ;
  • Kim, Chi Hong (Department of Internal Medicine, The Catholic University of Korea) ;
  • Dong Hwa, Han (Research Institute of Medical Science, St. Vincent Hospital) ;
  • Kim, Seung Joon (Department of Internal Medicine, The Catholic University of Korea) ;
  • Moon, Hwa Sik (Department of Internal Medicine, The Catholic University of Korea) ;
  • Song, Jeong Sup (Department of Internal Medicine, The Catholic University of Korea) ;
  • Park, Sung Hak (Department of Internal Medicine, The Catholic University of Korea)
  • 송소향 (가톨릭대학교 의과대학 내과학교실) ;
  • 김치홍 (가톨릭대학교 의과대학 내과학교실) ;
  • 한동화 (성빈센트병원 임상의학연구소) ;
  • 김승준 (가톨릭대학교 의과대학 내과학교실) ;
  • 문화식 (가톨릭대학교 의과대학 내과학교실) ;
  • 송정섭 (가톨릭대학교 의과대학 내과학교실) ;
  • 박성학 (가톨릭대학교 의과대학 내과학교실)
  • Received : 2004.06.30
  • Accepted : 2004.10.12
  • Published : 2004.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background : Airway remodeling of the asthmatic airway, the result of persistent inflammation in the bronchial wall, is associated with irreversible airway obstruction and the severity of asthma. Previous reports had represented that adminitering CpG-oligodeoxynucleotides (CpG-ODN) before sensitization or challenge by allergens inhibits the development of eosinophilic airway inflammation in a murine model of asthma, but the effects of CpG-ODNs on chronic inflammation and airway remodeling had not been characterized. To investigate the influence of CpG-ODNs on chronic inflammation and remodeling of the airway, we performed studies using a murine model of chronic allergen-induced asthma. Methods : Balb/C mice were sensitized to ovalbumin(OVA) and subsequently exposed to nebulized OVA by means of inhalation twice weekly for 7 weeks. CpG-ODNs($30{\mu}g$) was administered intraperitoneally at sensitization. After final inhalation, mice were evaluated for airway hyperresponsiveness, chronic airway inflammation and remodeling. Results : The mice exposed to chronic and recurrent airway challenge with OVA had persistent airway hyperresponsiveness, chronic inflammation and airway remodeling. Mice treated with CpG-ODNs exhibited decreased bronchial hyperresponsiveness, OVA-specific IgE, chronic inflammation and evidence of airway remodeling, including goblet cell hyperplasia and subepithelial fibrosis. Conclusion : CpG-ODNs was thought to prevent chronic inflammation and remodeling changes in a murine model of chronic asthma.

연구배경 : 급성천식 동물모델에 투여할 경우 특징적인 기도과민성이나 호산구성 염증 등이 호전되는 것으로 알려져 있으나, 만성천식 모델에서 기도의 만성염증 및 기도재구성을 억제할 수 있다는 연구는 많지 않다. CpG-ODN이 기도의 만성염증 및 기도재구성을 예방할 수 있는 지 알기위하여, 만성천식 마우스모델에서 CpG-ODN의 기도의 만성염증 및 기도재구성에 대한 영향을 연구하고자 하였다. 방 법 : BALB/C 마우스를 ovalbumin으로 감작시킨뒤 7주간 만성적인 자극을 주어 만성 천식모델을 만들고, CpG-ODN은 감작시에 복강내에 주사하였다. 7주후기 도저항(기도과민성)의 측정, 혈청 IgE의 측정, 기관지 폐포세척액에서 염증세포분획을 검사하였고, 폐조직검사로 염증세포의 침윤 및 기저막하부의 섬유화의 정도를 관찰하였고, OVA군과 CpG-ODN군과 비교하였다. 결 과 : 1) 기관지폐포세척액내 호산구는 CpG-ODN군은 OVA군에 비해 통계적으로 유의하게 감소하였다($0.9{\pm}0.8$ ; $9.7{\pm}5.8{\times}10^4/ml$, P<0.01). 2) 기도과민성은 CpG-ODN군은 OVA군에 비해서 기도과민성(Penh)이 $50mg/m{\ell}$를 제외한 농도에서 모두 유의하게 감소한 소견을 보였다(P<0.01). 3) 혈청 총 IgE는 CpG-ODN군이 OVA군에 비해 감소한 소견을 보였고($0.21{\pm}0.11$ ; $1.16{\pm}0.39{\mu}g/ml$, P<0.01), 혈청 OVA specific IgE도 CpG-ODN군이 OVA군에 비해 감소한 소견을 보였다($1.1{\pm}0.5$ ; $1.7{\pm}0.6$ OD units, P<0.01). 4) 배상세포의 증식정도는 CpG-ODN군은 OVA군에 감소된(P<0.01) 소견을 보였다. 5) 기저막하부의 섬유화의 정도는 CpG-ODN군이 OVA군에 비해서 유의하게 감소된(P<0.01) 소견을 보였다. 결 론 : CpG-ODN은 기도의 급성염증 및 기도과민성을 억제할 뿐만 아니라 만성천식 마우스모델에서 기도의 만성염증 및 기도재구성을 억제시킴을 알 수 있었다.

Keywords

References

  1. Rodie WR, Beaaley R, Wmlliams JH, Holeate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989;1:520 4
  2. Aikawa T, Shimura S, Sasaki H, Ebina M, Taki-shima T. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992;101: 916 21
  3. Bousquet J, Cbmez P, Lacoste JY, White R, Vic P, Godard P, et al. Asthma: a disease remodeling the airways. Allerey 1992:47:3-11
  4. Redington AE, Howarth PH. Airway wall remodeling in asthma. Thorax 1997;52:310-2
  5. Wilson JW, LiX, Pain MC. The lack of distensibaity of asthmatic airways. Am Rev Respir Dis 1993;148:806-9
  6. Boulet LP, Laviolette M, Turcotte H, Cartier A, Dugas M, Malo JL, et al. Bronchial subepithelial fibrosis coirelates with airway responsiveness to methadioline. Chest 1997; 112:45-52
  7. Jeffery PK, Goldfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantita-tive light and electron microscopic study. Am Rev Respir Dis 1992; 145:890-9
  8. Warshamana GS, Martinez S, Lasky JA, Corti M, Brody AR. Dexamethasone activates expression of the PDGF-alpha receptor and induces lung fibro-blast proliferation. Am J Physiol 1998;Z74:499-507
  9. Wohlleben G, Erb KJ. Atopic disorders: a vaccine around the comer? Trends Immunol 2001;22:618-26
  10. Chu RS, Tareoni OS, Kriee AM, Lehimnn PV, Harding CV. CpG oligodeoxynucleotides act as ad-juvants that switch on T helper 1 (Thl) immuoity. J Exp Med 1997;186:1623 31
  11. Kline JN, Waldschmidt TJ, Businea TR, Lemiah JE, Weinstock JV, Thorne PS, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Imniunol 1998:160:2555-9
  12. Tanaka H, Masuda T, Tokuoka S, Komai M, Naeao K, Takahashi Y, et al. The effect of allereen-induced airway inflarmation on airway remodelling in a murine model of allergic asthma. Inflamm Res 2001;50:616 24
  13. Temelkovaki J, Hoam SP, Shepherd DP, Foster PS, Kumar RK. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998;53:849-56
  14. Santeliz JV, Van Nest G, Traquina P, Larsen E, Waills Karp M. Amb a 1 linked CpG olieodeoxy-nueleotides reverse established airway hypeires-ponsiveness in a murine model of asthma. J Allergy Cin Immunol 2002;109(3):455-62
  15. Serebrisky D, Teper AA, Huane CK, Lee SY, ZhangTF, Schofield BH, et al. CpG oligodeoxynucel otides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol 2000;165:5906-12
  16. Sur S, Wad JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allcrgic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999;162: 6284-93
  17. Metzger WJ, Nyce JW. Olieonulceotide therapy ofallergic asthma. J Allergy Clin Immuriol 1999;104(2 pz 1):260 6
  18. Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK,Jain V, Businga TR. CpG oligodeoxynucleotides do not require THl cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol 1999;104(6):1258-64
  19. Kline JN, Waldschmidt TJ, Businea TR, Lemiah JE, Weinstock JV, Thorne PS, et al. Modulation of airway inflammation by CpG oligodeoxynudeotidesin a murine model of asthma. J Immunol 1998;160: 2555-9
  20. Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostmulatory DNA. Jpn J Infect Dis 1999;52:1-11
  21. Sun S, Zhane X, Toueh DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998;188:2335 42
  22. Bohle B, Jahn-Schmid B, Maurer D, Kraft D, EbnerC. Oligodexoynudeotides contaming CpG motifs induce IL-12, IL-18 and INF-gamma production imcells from allergic individuals and inhibit IgEsynthesis in vitro. Eur J Immunol 1999;29:2344-53
  23. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998;161(12):7054-62
  24. Sparwasser T, Koch ES, Vabulas RM, Heee K, Lipford GB, Ellwart JW, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998;28:2045-54
  25. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999; 96:9305-10
  26. Yamamoto S, Kuramoto E, Shimada S, Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-alphq/beta and-gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 1988;79:866-73
  27. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9
  28. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997;186:1623-31
  29. Peng Z, Wang H, Mao X, HayGlass KT, Simons FE. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. Int Immunol 2001;13:3-11
  30. Sparwasser T, Lipford G, Miethke T, Borscherz K, Hacker H, Heegk, et al. Bacterial DNA causes septic shock. Nature 1997;386:336-7
  31. Sparwaser T, Hultner L, Koch ES, Luz A, Lipford GB, Wagner H. Immunostimulatory CpG-oligode-oxynuelcleotides cause extramedullary murine hemopoiesis. J Immunol 1999;162:2368-74
  32. Tsunoda I, Tolley ND, Theil DJ, Whitton JL, Kobayashi H, Fuhinami RS. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol 1999;9:481-93